MapLight CSO sells 22,082 shares under 10b5-1 plan
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics, Inc., reported selling 22,082 shares of Voting Common Stock on August 3, 2026 at a weighted average price of $12.54 per share, in transactions ranging from $12.12 to $12.99, pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025. Following this sale, Woodruff directly holds 202,380 shares of the company’s common stock.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Voting Common Stock F1, F2 | 22,082 | $12.54 | $277K |
Footnotes (2)
- F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.12 to $12.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
Voting Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MapLight Therapeutics (MPLT) disclose for its Chief Scientific Officer?
Was the MapLight Therapeutics (MPLT) insider sale made under a Rule 10b5-1 plan?
What does the weighted average price mean in MapLight Therapeutics (MPLT)’s insider sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.